Neukio Biotherapeutics

A bevy of big venture capital financings have been announced since Labor Day, the official end of summer in the US, led by a $300m series C round for Acelyrin, Inc. The boom in VC mega-deals is rema

Eager to get ahead, gene therapy and gene-editing companies in China are now racing to secure funding and get their treatments in front of patients. Given the promise these modalities potentially offe

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Orange Grove, SV Investment Align With

Adaptimmune Therapeutics plc has a powerful new partner in Roche Holding AG ’s Genentech for its allogeneic T-cell therapy program, based on Adaptimmune’s induced pluripotent stem cell (iPSC)-derive